Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-κB activation and PPAR transcriptional activity.

In the screening search for NF-κB inhibitory and PPAR transactivational agents from medicinal plants, a methanol extract of the whole plant of Tacca plantaginea and its aqueous fraction showed the significant activities. Bioassay-guided fractionation combined with repeated chromatographic separation of the aqueous fraction of the methanol extract of T. plantaginea resulted in the isolation of two new diarylheptanoid glycosides, plantagineosides A (1) and B (2), an unusual new cyclic diarylheptanoid glycoside, plantagineoside C (3), and three known compounds (4-6). Their structures were determined by extensive spectroscopic and chemical methods. Compounds 3-6 significantly inhibited TNFα-induced NF-κB transcriptional activity in HepG2 cells in a dose-dependent manner, with IC(50) values ranging from 0.9 to 9.4 μM. Compounds 1-6 significantly activated the transcriptional activity of PPARs in a dose-dependent manner, with EC(50) values ranging from 0.30 to 10.4 μM. In addition, the transactivational effects of compounds 1-6 were evaluated on three individual PPAR subtypes, including PPARα, γ, and β(δ). Compounds 1-6 significantly enhanced the transcriptional activity of PPARβ(δ), with EC(50) values in a range of 11.0-30.1 μM. These data provide the rationale for using T. plantaginea and its components for the prevention and treatment of inflammatory and metabolic diseases.

[1]  V. Pande,et al.  NF-kappaB in human disease: current inhibitors and prospects for de novo structure based design of inhibitors. , 2005, Current medicinal chemistry.

[2]  M. Haluzík.  PPAR-α and Insulin Sensitivity , 2006 .

[3]  Sander Kersten,et al.  Roles of PPARs in health and disease , 2000, Nature.

[4]  W. Koenig,et al.  Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators , 1998, Nature.

[5]  B. L. Bálint,et al.  Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases. , 2006, Endocrine, metabolic & immune disorders drug targets.

[6]  Michael Lehrke,et al.  The Many Faces of PPARγ , 2005, Cell.

[7]  Haiyang Liu,et al.  Plantagiolide F, a minor withanolide from Tacca plantaginea , 2011, Natural product research.

[8]  R. Evans,et al.  PPARδ: a dagger in the heart of the metabolic syndrome , 2006 .

[9]  Hiroshi Sakagami,et al.  New diarylheptanoids and diarylheptanoid glucosides from the rhizomes of Tacca chantrieri and their cytotoxic activity. , 2002, Journal of natural products.

[10]  Robert Kleemann,et al.  Global Suppression of IL-6-induced Acute Phase Response Gene Expression after Chronic in Vivo Treatment with the Peroxisome Proliferator-activated Receptor-α Activator Fenofibrate* , 2004, Journal of Biological Chemistry.

[11]  J. Holder,et al.  PPAR-γ agonists: therapeutic role in diabetes, inflammation and cancer , 2000 .

[12]  Y. Mimaki,et al.  Chantriolides A and B, two new withanolide glucosides from the rhizomes of Tacca chantrieri. , 2003, Journal of natural products.

[13]  H. Kikuzaki,et al.  Cyclic diarylheptanoids from rhizomes of Zingiber officinale , 1996 .

[14]  B. Vergès.  Clinical interest of PPARs ligands. , 2004, Diabetes & metabolism.

[15]  Akihito Yokosuka,et al.  Steroidal and pregnane glycosides from the rhizomes of Tacca chantrieri. , 2002, Journal of natural products.

[16]  G. Hofmann,et al.  Isolation and structure elucidation of new PKCalpha inhibitors from Pinus flexilis. , 1998, Journal of natural products.

[17]  Jerrold M. Olefsky,et al.  PPARδ regulates glucose metabolism and insulin sensitivity , 2006 .

[18]  M. Karin,et al.  The two NF-κB activation pathways and their role in innate and adaptive immunity , 2004 .

[19]  C. Glass,et al.  Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms. , 2007, Trends in immunology.

[20]  A. Billin,et al.  The next generation of PPAR drugs: do we have the tools to find them? , 2007, Biochimica et biophysica acta.

[21]  Haiyang Liu,et al.  Five new withanolides from Tacca plantaginea. , 2006, Chemical & pharmaceutical bulletin.

[22]  S. Kersten,et al.  Peroxisome proliferator-activated receptor α target genes , 2004, Cellular and Molecular Life Sciences CMLS.

[23]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[24]  J. Ward,et al.  Growth, Adipose, Brain, and Skin Alterations Resulting from Targeted Disruption of the Mouse Peroxisome Proliferator-Activated Receptor β(δ) , 2000, Molecular and Cellular Biology.

[25]  A. Baldwin.  Series Introduction: The transcription factor NF-κB and human disease , 2001 .

[26]  H. Otsuka,et al.  New diarylheptanoids from Amomum muricarpum ELMER. , 2006, Chemical & pharmaceutical bulletin.

[27]  Haiyang Liu,et al.  Taccalonolides W-Y, three new pentacyclic steroids from Tacca plantaginea , 2008 .

[28]  R. Evans,et al.  The steroid and thyroid hormone receptor superfamily. , 1988, Science.

[29]  R. Evans,et al.  Effects of peroxisome proliferator-activated receptor δ on placentation, adiposity, and colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  B. Staels,et al.  PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[31]  S. Ohta.  The Solvent Effects on the Optical Rotatory Properties of 1,7-Diaryl-5-hydroxy-3-heptanones and Related Compounds , 1986 .

[32]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[33]  I. Verma,et al.  NF-κB regulation in the immune system , 2002, Nature Reviews Immunology.

[34]  M. Lazar.  PPARγ, 10 years later , 2005 .

[35]  A. Mühlbauer,et al.  Five Novel Taccalonolides from the Roots of the Vietnamese Plant Tacca paxiana , 2003 .